false
--12-31
0000001800
Common Shares, Without Par Value
ABT
0000001800
2025-12-12
2025-12-12
0000001800
us-gaap:CommonStockMember
exch:XCHI
2025-12-12
2025-12-12
0000001800
us-gaap:CommonStockMember
exch:XNYS
2025-12-12
2025-12-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
| Common Shares, Without Par Value |
|
ABT |
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
December 12, 2025
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in
charter)
| Illinois |
|
1-2189 |
|
36-0698440 |
| (State or other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of Incorporation) |
|
|
|
Identification No.) |
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number, including
area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of
the Act:
| Title of Each Class |
Trading
Symbol(s) |
Name of Each Exchange
on Which Registered |
| Common
Shares, Without Par Value |
ABT |
New
York Stock Exchange
NYSE Texas |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers. |
On December 12, 2025, Nita Ahuja, M.D. was named to the Abbott Laboratories’
(“Abbott”) Board of Directors.
| Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On December 12, 2025, Abbott’s Board of Directors amended the
first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of
thirteen persons, effective as of December 12, 2025. Abbott’s by-laws previously provided that the Board of Directors consisted
of twelve persons.
| Item 9.01 | Financial Statements and Exhibits. |
| | Exhibit No. | Exhibit |
| | | |
| 99.1 | By-Laws of Abbott Laboratories, as amended and restated, effective December 12, 2025. |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABBOTT LABORATORIES |
| |
|
| Date: December 12, 2025 |
By: |
/s/ Philip P. Boudreau |
| |
|
Philip P. Boudreau |
| |
|
Executive Vice President, Finance and Chief Financial
Officer |
